Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy

Clin Biochem. 2008 Jul;41(10-11):785-95. doi: 10.1016/j.clinbiochem.2008.04.001. Epub 2008 Apr 11.

Abstract

Objectives: A population kinetic approach based on PSA clearance (CL(PSA)) may be a more rational strategy to characterize prostate-specific antigen (PSA) decrease profile after prostate surgery than the commonly used method (half-life from mono/bi-exponential models).

Methods: We used 182 post-adenomectomy PSA concentrations from 56 benign prostatic hyperplasia patients to build, with NONMEM software, a multi-exponential and a CL(PSA) model for comparison.

Results: The best multi-exponential model was PSA(t)=4.96e(-)(0.269t)+3.10e(-)(0.16t)+0.746e(+)(0.0002t) with a stable median residual PSA at 0.64 ng/mL. The best model parametrized with clearance was CL(PSA)=0.0229()(AGE/69)(3.78). Akaike information criteria and standard errors favored the CL(PSA) model. Median peripheral zone and transitional zone productions were 0.034 ng/mL/cm(3) and 0.136 ng/mL/g. A threshold at 2 ng/mL on day 90 allowed for a diagnostic of biochemical relapse diagnostic.

Conclusions: The population CL(PSA) model was superior to the multi-exponential approach for investigating individual post-adenomectomy PSA decreases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / blood
  • Adenoma / surgery*
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / metabolism
  • Blood Cell Count
  • Blood Proteins / metabolism
  • Creatinine / blood
  • Humans
  • Kinetics
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Prostate-Specific Antigen / blood
  • Prostate-Specific Antigen / metabolism*
  • Prostatic Hyperplasia / blood
  • Prostatic Hyperplasia / surgery
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / surgery*

Substances

  • Biomarkers, Tumor
  • Blood Proteins
  • Creatinine
  • Prostate-Specific Antigen